Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 63Lymphoid 38Other hematologic neoplasm 20Thoracic 8Gastrointestinal 6Dermatologic 6Myeloid 4Genitourinary 4Other solid neoplasm 3Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Somatostatinoma 1Pancreatic Neoplasms 1Insulinoma 1Glucagonoma 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bortezomib × Endocrine × Clear all
NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡